News releases

Merck Issues Statement on GARDASIL® Litigation

RAHWAY, N.J., Jan. 28, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today reaffirmed its commitment to defending the safety and efficacy of its HPV vaccines.

Merck is a defendant in product liability lawsuits in the United States involving GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant).

In response to the trial, which began jury selection on January 22 in California, Merck issued the following statement:

“At Merck, the safety of our medicines and vaccines and the wellbeing of the people who take them are our top priority. An overwhelming body of scientific evidence, including more than 30 years of research and development along with real world evidence generated by Merck and by independent investigators, continues to support the safety and efficacy profiles of our HPV vaccines. The plaintiff’s allegations have no merit, and we remain committed to vigorously defending against these claims in the upcoming trial.”

For more information about GARDASIL and GARDASIL 9, visit www.gardasil9facts.com.

ที่มา: https://www.merck.com/news/merck-issues-statement-on-gardasil-litigation/

TH-HPV-00563 02/2025

###